FDA Approves Savaysa (edoxaban) to Prevent Embolic Events in Non-Valvular Atrial Fibrillation

January 8, 2015 — The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not…
Drugs.com – New Drug Approvals

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us